Last reviewed · How we verify
Intra-Arterial TNK
TNK (tenecteplase) is a fibrinolytic agent that dissolves blood clots by converting plasminogen to plasmin when administered directly into an artery.
TNK (tenecteplase) is a fibrinolytic agent that dissolves blood clots by converting plasminogen to plasmin when administered directly into an artery. Used for Acute ischemic stroke (intra-arterial administration).
At a glance
| Generic name | Intra-Arterial TNK |
|---|---|
| Sponsor | Tianjin Huanhu Hospital |
| Drug class | Fibrinolytic agent / Thrombolytic |
| Target | Plasminogen / Fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Neurology |
| Phase | Phase 3 |
Mechanism of action
TNK is a genetically engineered variant of tissue plasminogen activator (tPA) with enhanced fibrin specificity and longer half-life. When delivered intra-arterially, it directly activates the fibrinolytic cascade at the site of thrombosis, promoting rapid clot dissolution. This approach is used in acute ischemic stroke to restore blood flow to affected brain tissue.
Approved indications
- Acute ischemic stroke (intra-arterial administration)
Common side effects
- Intracranial hemorrhage
- Symptomatic intracerebral hemorrhage
- Reperfusion injury
- Systemic bleeding
Key clinical trials
- Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO) (PHASE3)
- Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions (PHASE3)
- Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke (PHASE3)
- Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial (PHASE2, PHASE3)
- IAT-MeVO Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial (NA)
- Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion (PHASE3)
- Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK) (NA)
- Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intra-Arterial TNK CI brief — competitive landscape report
- Intra-Arterial TNK updates RSS · CI watch RSS
- Tianjin Huanhu Hospital portfolio CI